HIV provider endorsement of primary care buprenorphine treatment: a vignette study.
OBJECTIVE
Opioid dependence is common among HIV-infected persons in the United States. Factors associated with HIV care providers recommending buprenorphine for opioid dependence are poorly defined. Using vignettes, we sought to identify HIV provider characteristics associated with endorsing buprenorphine treatment in primary care.


METHODS
We used a cross-sectional survey of HIV providers, including 497 physicians, nurse practitioners, and physician assistants attending HIV educational conferences in 2006. Anonymous questionnaires distributed to conference attendees contained one of two vignettes depicting opioid-dependent patients. Respondents recommended type of substance abuse treatment for the vignette patient. Using logistic regression, we tested patient and provider factors associated with HIV provider endorsement of buprenorphine in primary care.


RESULTS
Sixteen percent of providers endorsed buprenorphine treatment in primary care for vignette patients. Family physicians and general internists (AOR=2.8, CI=1.1-7.1), African American providers (AOR=3.0, CI=1.3-6.8), and those with previous buprenorphine prescribing experience (AOR=4.6, CI=1.2-17.9) were more likely to endorse buprenorphine treatment in primary care.


CONCLUSIONS
HIV providers infrequently endorsed buprenorphine treatment in primary care for vignette patients. Generalist and African American providers and those with previous buprenorphine prescribing experience are more likely to endorse buprenorphine treatment in primary care. Targeting generalist and minority providers may be one strategy to promote effective integration of HIV care and opioid addiction treatment.
Kunins
Hillary V
HV
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10467, USA. hkunins@montefiore.org
Sohler
Nancy L
NL
Roose
Robert J
RJ
Cunningham
Chinazo O
CO
D001291:Attitude of Health Personnel; D044383:Black People; D002047:Buprenorphine / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005194:Family Practice; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007388:Internal Medicine; D008297:Male; D008875:Middle Aged; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D011320:Primary Health Care; D011795:Surveys and Questionnaires; D001741:Black or African American
D009292:Narcotic Antagonists; D002047:Buprenorphine